Karyopharm Therapeutics | KPTI - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Abbott USD 6.8B 1.72B 2026-03
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Incyte USD 4.02B 435.22M 2026-03
J&J USD 21.69B 1.98B 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
MacroGenics USD 66.52M 9.3M 2026-03
Merck USD 5.33B 9.24B 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Novartis USD 6.88B 4.56B 2026-03
Novartis USD 6.88B 2.68B 2026-03
Pfizer USD 1.7B 561M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Takeda JPY 654.94B 26.55B 2025-12
Tectonic Therapeutic USD 236.89M 16.9M 2026-03
TG Therapeutics USD 442.21M 242.7M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Xencor USD 14.17M 39.9M 2026-03